Aztreonam inhalation - Gilead Sciences
Alternative Names: AI - Gilead; AZLI; Aztreonam lysine; Cayston; Corus 1020; GS-9268Latest Information Update: 28 Apr 2023
At a glance
- Originator Gilead Sciences
- Class Antibacterials; Monobactams; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis-associated respiratory tract infections
- Phase III Bronchiectasis
- Discontinued Burkholderia infections
Most Recent Events
- 28 Apr 2023 Gilead Sciences initiates a phase II VitalBE trial in Bronchiectasis (Inhalation, Aerosol) (NCT03696290)
- 27 Apr 2023 Phase-III clinical trials in Bronchiectasis (Non-cystic fibrosis-related) in United Kingdom (Inhalation)
- 18 Mar 2023 Health Canada announces recall of two lots (032168 and 033357) of aztreonam inhalation (Cayston®) in Canada by Gilead Sciences, due to the potential of cracked glass vials in the lots